Promise already turning into fact: management shows the thing it told investors was coming is now measurably arriving, a
The model's full reasoning — Q4 2022 call → NOWe need answer YES/NO. Need analyze transcript for pattern. Need be careful. Question asks: Does management point to a growth-bearing development in its business that IT HAD PREVIOUSLY TOLD INVESTORS TO EXPECT — and demonstrate, with real current-period activity, that this development is NOW ACTUALLY ARRIVING at or beyond pace, while also conveying still early? Need identify if management refers back to prior expectation, current confirmation, still early. In transcript, management discusses FDA submissions, product pipeline, partnerships, LIVMOR acquisition, patents. Need see if any growth-bearing development previously promised and now confirmed with real current activity. They mention HeartBeam AIMI 510(k) submission previously announced, received FDA questions, responded, expect clearance Q2, limited market release early Q3. AIMIGo V1 submission expected shortly, V2 targeted Q4. They partnered with Evolve. They acquired LIVMOR. They strengthened IP. But do they point to prior expectation and current activity confirming? They say "We previously announced the 510(k) submission of our HeartBeam AIMI platform to the FDA. We received questions from FDA within statutory 30 day review deadline, discussed questions via teleconference, provided written responses... substantive review in progress, expect clearance Q2." That is a development (FDA clearance) previously expected, now progressing. But is that growth-bearing? It's regulatory milestone, not actual growth in business. They also say "We expect to file V1 submission shortly" etc. No actual orders/revenue. They mention "we continue to engage with potential customers and partners in anticipation of FDA clearance" - not real current activity. They mention "we have a deep product pipeline" but no confirmation. Need see if management says "as we said" or "we previously announced" - yes for AIMI submission. But current reality? They received questions and responded, not product growth. Still early? They expect clearance and limited market release. But is that "growth-bearing development" arriving? It's regulatory approval, not business growth. The question specifically: "growth-bearing development in its business" e.g. ramp, launch, recovery, adoption, expansion. FDA submission/clearance is a step toward launch, not growth itself.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| MDLZ | Mondelez International, Inc. | Q4 2016 | 2017-02-07 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| F | Ford Motor Company | Q3 2016 | 2016-10-27 | B+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
ICFI · Q1 2017 → YESThe question is: Does management point to a growth-bearing development that they previously told investors to expect, and now it's arriving with current activity, but still early with most contributio...YES Management explicitly references the themes from their February 2017 full-year earnings call (only two months prior), noting that the January-February pickup they had highlighted there continued through March. They then point to concrete current-period activity: ICF Olson won over $75 million in new revenue since acquisition (neither firm could have won independently), added substantial new-account wins in Q1, and saw its qualified pipeline rise significantly above year-end 2016 levels. John Wasson confirms the new projects and retainers are now lining up, with strong Q1 wins and momentum from added staff. Sudhakar states they expect mid-single-digit growth this 2017 and sequential improvement, while reiterating confidence in the medium-term outlook. The language makes clear the ramp is still early—H2 comparisons and most of the contribution lie ahead—matching the three-part pattern for this growth-bearing development. No other item in the call satisfies all three criteria as cleanly.
HOLX · Q4 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES The transcript shows a clear three-part pattern for international growth. Management explicitly references its prior expectation: “while we thought that international would be a double-digit grower by 2018, we've actually delivered on that promise a year earlier than anticipated.” In the just-reported Q4, they confirm the development with concrete activity 17.5% international growth (excluding Cynosure and blood), the sixth consecutive quarter of double-digit growth for molecular internationally, and Panther shipments exceeding prior-year levels. They also state it is still early with most contribution ahead: “we've actually delivered on that promise a year earlier,” and they hope investors remember this 2017 success story as they evaluate Cynosure 2.
PTC · Q3 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES Management explicitly references its prior long-term growth ambition for IoT (30-40% bookings growth, consistent with the faster-growing IoT market) as part of its double-digit overall plan, which it had communicated as the target to achieve sustainable growth. In the current quarter, it confirms this is materializing with 40%+ of IoT bookings from customer expansions, six-figure deals growing sequentially and year-over-year, and specific closed expansions with leading food/beverage, aerospace/defense, and medical device companies, plus strong contribution from these. It further conveys the development remains early by noting customers are "generally still in the early days of their IoT journeys" with "adoption is gaining momentum" and "further stages" (e.g.